ResultsIQ

ResultsIQ › Latest results › Piramal Pharma Limited

Piramal Pharma Limited Q4 FY25 results deck summary

NSE: PPLPHARMA · BSE: 543635

Results deck of 14 May 2025, summarised by AI from the filing.

US$2+ bn revenue with 25% EBITDA margin, excluding inorganic growth

Key takeaways

  1. FY2030 target US$2+ bn revenue with 25% EBITDA margin, excluding inorganic growth
  2. Net debt Net debt to EBITDA improved to 2.7x in FY25 from 5.6x in FY23
  3. CDMO growth On-patent commercial manufacturing revenues grew over 50% YoY to US$179 mn in FY25
  4. CHG margin EBITDA margins moderated due to non-recurring expenses and capacity expansion; recovery expected from FY26

Original filing on BSE

Piramal Pharma Limited Q1 FY27 results

As filed: Revenue ₹2,270 cr (+17% year on year), EBITDA ₹195 cr (+84% year on year), PAT −₹69.4 cr, EBITDA margin 8.6% (+312 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹2,752 cr (0% year on year), EBITDA ₹461 cr (−18% year on year), PAT −₹8.8 cr (−20% year on year), EBITDA margin 16.7% (−367 bps). Score 26 of 100, Below trend. Revenue and EBITDA growth were below the company's own trend; profit before exceptional items growth was in line with it. EBITDA margin fell 367 bps year on year. Other income 157% of PBT. Tax rate 176%. Share price after the results: +5.9% in 29 days (Nifty 500: +0.9%).
  • Q3 FY26: Revenue ₹2,140 cr (−3% year on year), EBITDA ₹196 cr (−42% year on year), PAT −₹136 cr (−226% year on year), EBITDA margin 9.2% (−619 bps). Score 17 of 100, Below trend. Revenue and profit before exceptional items growth were well below the company's own trend; EBITDA growth was below it. EBITDA margin fell 619 bps year on year. Consolidated profit -3505% but standalone +8%. Share price after the results: +3.4% in 29 days (Nifty 500: +0.4%).
  • Q2 FY26: Revenue ₹2,044 cr (−9% year on year), EBITDA ₹158 cr (−54% year on year), PAT −₹99.0 cr (−300% year on year), EBITDA margin 7.7% (−752 bps). Score 10 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 752 bps year on year. Share price after the results: −10.3% in 30 days (Nifty 500: +0.7%).
  • Q1 FY26: Revenue ₹1,934 cr (−1% year on year), EBITDA ₹106 cr (−48% year on year), PAT −₹82.0 cr, EBITDA margin 5.5% (−503 bps). Score 12 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend. EBITDA margin fell 503 bps year on year. Revenue fell 30% from last quarter. Revenue rose ₹-17.0 cr on a year ago, against ₹202 cr the year before. Share price after the results: −7.3% in 29 days (Nifty 500: −0.3%).
  • Q4 FY25: Revenue ₹2,754 cr (+8% year on year), EBITDA ₹562 cr (+6% year on year), PAT ₹154 cr (+52% year on year), EBITDA margin 20.4% (−36 bps). Score 23 of 100, Below trend. Revenue growth was well below the company's own trend; EBITDA growth was below it. EBITDA margin fell 36 bps year on year. Tax rate 46%. Revenue rose ₹202 cr on a year ago, against ₹388 cr the year before. Share price after the results: −8.6% in 30 days (Nifty 500: +1.8%).
  • Q3 FY25: Revenue ₹2,204 cr (+13% year on year), EBITDA ₹338 cr (+27% year on year), PAT ₹4.0 cr (−60% year on year), EBITDA margin 15.3% (+171 bps). Score 32 of 100, Below trend. Revenue and EBITDA growth were below the company's own trend. EBITDA margin rose 171 bps year on year. Tax rate 126%. Consolidated profit -60% but standalone +61%. Profit fell 83% from last quarter. Revenue rose ₹245 cr on a year ago, more than the ₹243 cr it added the year before.
  • Q2 FY25: Revenue ₹2,242 cr (+17% year on year), EBITDA ₹342 cr (+29% year on year), PAT ₹23.0 cr (+300% year on year), EBITDA margin 15.3% (+133 bps). Score 65 of 100, Above trend. EBITDA margin rose 133 bps year on year. Other income 59% of PBT. Tax rate 94%. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Piramal Pharma Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.